Oncology company MEI Pharma Inc (Nasdaq:MEIP) disclosed on Tuesday that its net income was USD2.7m (USD0.07 per share) for its fiscal year ended 30 June 2017.
This reflects an improvement in earnings when compared with a net loss of USD20.9m (USD0.61 per share) for 2016.
Revenues of USD23.2m related to the Helsinn License Agreement were generated for the year ended 30 June 2017 , a rise from nil in 2016.
For the year ended 30 June 2017, the cost of research and development revenue, comprised primarily of reimbursable third-party pass-through costs, was USD5.0m.
Research and development expenses of USD7.2m were recorded for the year ended 30 June 2017, a decline over R&D expenses of USD13.4m for 2016, which was primarily due to a reduction in expenses related to pracinostat pursuant to the Helsinn License Agreement.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva